BMO Capital Markets reaffirmed their outperform rating on shares of Horizon Pharma Inc. (NASDAQ:HZNP) in a research report sent to investors on Monday morning. They currently have a $29.00 target price on the biopharmaceutical company’s stock.

Other equities research analysts also recently issued reports about the stock. Citigroup Inc. raised shares of Horizon Pharma from a neutral rating to a buy rating in a report on Monday. Mizuho reissued a buy rating and issued a $30.00 price target (up from $24.00) on shares of Horizon Pharma in a report on Wednesday, August 10th. Brean Capital reissued a buy rating and issued a $30.00 price target on shares of Horizon Pharma in a report on Tuesday, August 9th. Morgan Stanley set a $24.00 price target on shares of Horizon Pharma and gave the stock a hold rating in a report on Monday, September 12th. Finally, Zacks Investment Research downgraded shares of Horizon Pharma from a buy rating to a hold rating in a report on Thursday, August 11th. One research analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of Buy and a consensus target price of $29.62.

Analyst Recommendations for Horizon Pharma (NASDAQ:HZNP)

Shares of Horizon Pharma (NASDAQ:HZNP) opened at 21.18 on Monday. Horizon Pharma has a 12-month low of $13.05 and a 12-month high of $23.44. The company’s market capitalization is $3.42 billion. The firm’s 50-day moving average is $18.75 and its 200-day moving average is $18.60.

Horizon Pharma (NASDAQ:HZNP) last announced its quarterly earnings results on Monday, November 7th. The biopharmaceutical company reported $0.70 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.63 by $0.07. Horizon Pharma had a negative net margin of 1.34% and a positive return on equity of 22.73%. The firm had revenue of $273.70 million for the quarter, compared to the consensus estimate of $270.04 million. During the same period in the prior year, the firm posted $0.70 earnings per share. The company’s revenue for the quarter was up 20.8% on a year-over-year basis. On average, equities analysts predict that Horizon Pharma will post $2.02 EPS for the current year.

COPYRIGHT VIOLATION WARNING: “Horizon Pharma’s (HZNP) “Outperform” Rating Reaffirmed at BMO Capital Markets” was first posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and reposted in violation of U.S. & international copyright & trademark legislation. The correct version of this report can be accessed at https://www.thecerbatgem.com/2016/11/29/horizon-pharmas-hznp-outperform-rating-reaffirmed-at-bmo-capital-markets.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. FMR LLC boosted its position in shares of Horizon Pharma by 1.7% in the second quarter. FMR LLC now owns 23,353,416 shares of the biopharmaceutical company’s stock valued at $384,631,000 after buying an additional 401,302 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Horizon Pharma by 7.5% in the second quarter. Vanguard Group Inc. now owns 10,569,177 shares of the biopharmaceutical company’s stock valued at $174,074,000 after buying an additional 737,812 shares in the last quarter. BlackRock Fund Advisors boosted its position in shares of Horizon Pharma by 5.6% in the third quarter. BlackRock Fund Advisors now owns 7,052,901 shares of the biopharmaceutical company’s stock valued at $127,869,000 after buying an additional 374,765 shares in the last quarter. JPMorgan Chase & Co. boosted its position in shares of Horizon Pharma by 28.6% in the second quarter. JPMorgan Chase & Co. now owns 4,341,698 shares of the biopharmaceutical company’s stock valued at $71,508,000 after buying an additional 964,505 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Horizon Pharma by 149.1% in the second quarter. State Street Corp now owns 4,201,164 shares of the biopharmaceutical company’s stock valued at $69,194,000 after buying an additional 2,514,430 shares in the last quarter. Hedge funds and other institutional investors own 86.91% of the company’s stock.

About Horizon Pharma

Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.

5 Day Chart for NASDAQ:HZNP

Receive News & Stock Ratings for Horizon Pharma Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma Inc. and related stocks with our FREE daily email newsletter.